These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29316633)

  • 21. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
    Garbes L; Riessland M; Hölker I; Heller R; Hauke J; Tränkle C; Coras R; Blümcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2009 Oct; 18(19):3645-58. PubMed ID: 19584083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
    Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns.
    Doktor TK; Hua Y; Andersen HS; Brøner S; Liu YH; Wieckowska A; Dembic M; Bruun GH; Krainer AR; Andresen BS
    Nucleic Acids Res; 2017 Jan; 45(1):395-416. PubMed ID: 27557711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy.
    Osman EY; Washington CW; Kaifer KA; Mazzasette C; Patitucci TN; Florea KM; Simon ME; Ko CP; Ebert AD; Lorson CL
    Mol Ther; 2016 Sep; 24(9):1592-601. PubMed ID: 27401142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.
    Mattis VB; Butchbach ME; Lorson CL
    J Neurosci Methods; 2008 Oct; 175(1):36-43. PubMed ID: 18771690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.
    Ramos DM; d'Ydewalle C; Gabbeta V; Dakka A; Klein SK; Norris DA; Matson J; Taylor SJ; Zaworski PG; Prior TW; Snyder PJ; Valdivia D; Hatem CL; Waters I; Gupte N; Swoboda KJ; Rigo F; Bennett CF; Naryshkin N; Paushkin S; Crawford TO; Sumner CJ
    J Clin Invest; 2019 Nov; 129(11):4817-4831. PubMed ID: 31589162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.
    Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP
    Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells.
    Zhou M; Hu Z; Qiu L; Zhou T; Feng M; Hu Q; Zeng B; Li Z; Sun Q; Wu Y; Liu X; Wu L; Liang D
    Hum Gene Ther; 2018 Nov; 29(11):1252-1263. PubMed ID: 29598153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
    Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
    Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.
    Hua Y; Sahashi K; Hung G; Rigo F; Passini MA; Bennett CF; Krainer AR
    Genes Dev; 2010 Aug; 24(15):1634-44. PubMed ID: 20624852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypothermia improves disease manifestations in SMA mice via SMN augmentation.
    Tsai LK; Chen CL; Tsai YC; Ting CH; Chien YH; Lee NC; Hwu WL
    Hum Mol Genet; 2016 Feb; 25(4):631-41. PubMed ID: 26647309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy.
    See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C
    Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
    Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
    Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.
    Butchbach ME; Singh J; Thorsteinsdóttir M; Saieva L; Slominski E; Thurmond J; Andrésson T; Zhang J; Edwards JD; Simard LR; Pellizzoni L; Jarecki J; Burghes AH; Gurney ME
    Hum Mol Genet; 2010 Feb; 19(3):454-67. PubMed ID: 19897588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
    Leckie J; Yokota T
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
    Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
    Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.
    Farooq F; Abadía-Molina F; MacKenzie D; Hadwen J; Shamim F; O'Reilly S; Holcik M; MacKenzie A
    Hum Mol Genet; 2013 Sep; 22(17):3415-24. PubMed ID: 23656793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.